(Q37316731)

19 August 2017

0 references

Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT. (English)

1 reference

19 August 2017

1 reference

gastric adenocarcinoma

1 reference

So Young Yoon

1

1 reference

19 August 2017

Sung-Yong Kim

2

1 reference

19 August 2017

Yo-Han Cho

3

1 reference

19 August 2017

Hyun Woo Chung

4

1 reference

19 August 2017

Young So

5

1 reference

19 August 2017

Hong M Lee

6

1 reference

19 August 2017

30 June 2009

1 reference

Cancer Research and Treatment

19 August 2017

1 reference

19 August 2017

41

1 reference

19 August 2017

2

1 reference

19 August 2017

100-103

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 August 2017

start time

30 June 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

Targeted therapy for metastatic renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

We should desist using RECIST, at least in GIST.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2731211

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19707508

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4143/CRT.2009.41.2.100

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19707508

1 reference